Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
$1000 Invested In Seagen 15 Years Ago Would Be Worth This Much Today
Seagen (NASDAQ:SGEN) has outperformed the market over the past 15 years by 14.65% on an annualized basis producing an average annual return of 21.09%. Currently, Seagen has a market capitalization of... 
Via Benzinga
Why Merck's Rumored $40 Billion Seagen Buyout Is On Shaky Ground
The deal is expected to cost Merck roughly $40 billion. 
Via Investor's Business Daily
This Favorable Sign Appears On Seagen's Chart
If history is any guide, there may be good fortune ahead for shares of Seagen (NASDAQ:SGEN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
Check Out What Whales Are Doing With SGEN
A whale with a lot of money to spend has taken a noticeably bullish stance on Seagen. Looking at options history for Seagen (NASDAQ:SGEN) we detected 10 strange trades. 
Via Benzinga
Where Seagen Stands With Analysts
Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022
From Seagen Inc.
Via Business Wire
This Analyst Believes Seagen Is Evaluating Strategic Alternatives
Via Benzinga
Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ
Via Benzinga
Merck Reportedly Eyes $40 Billion Seagen Tie-Up; Will The Deal Save Biotech?
Two major cancer players are reportedly closing in on a massive merger. 
Via Investor's Business Daily
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
Seagen (SGEN) Stock Pops on Merck Buyout Rumors
Seagen (SGEN) stock is getting a boost on Thursday as rumors circulate that Merck (MRK) is considering a buyout of the biotechnology company. 
Via InvestorPlace
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Merck Is Sending Seagen Stock Higher Today
Seagen Inc (NASDAQ: SGEN) shares are trading higher Thursday following reports suggesting Merck & Company Inc (NYSE: MRK) is in advanced talks to acquire the company. 
Via Benzinga
Where Seagen Stands With Analysts
Analysts have provided the following ratings for Seagen (NASDAQ:SGEN) within the last quarter: 
Via Benzinga
Benzinga Before The Bell: Elon Musk's Kids, Apple's Potential Security Measure, Covid-19 Vaccine Wastage And Other Top Financial Stories Thursday, July 7
CNBC 
Via Benzinga
Merck's Potential Buyout Of Seagen Expected Within Next Few Weeks: Report
Via Benzinga
5 Best And Worst Performing Large-Cap Stocks In June 2022
Over the past decade or so, these large-cap stocks have outperformed their smaller peers. Let’s take a look at the five best and worst performing large-cap stocks in June 2022. 
Via Talk Markets
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Seagen's Tucatinib/Trastuzumab Combo Shows Encouraging Antitumor Activity In Pretreated Colorectal Cancer Patients
Via Benzinga
Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,400 Today
Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 18.41% on an annualized basis producing an average annual return of 27.81%. Currently, Seagen has a market capitalization of... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2022
Upgrades 
Via Benzinga
Seagen Surges As Merck Takeover Deal Reportedly Accelerating
The news comes after ex-CEO Clay Siegall was arrested on domestic violence charges. 
Via Investor's Business Daily
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24
Reuters 
Via Benzinga
SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know
SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN). 
Via Benzinga
SGEN Stock Alert: Is Merck About to Buy Seagen?
Today, various reports have highlighted a potential deal for Merck to buy out Seagen, taking SGEN stock on a nice ride this afternoon. 
Via InvestorPlace
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
33 Stocks Moving In Friday's Mid-Day Session
Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.